课题基金 / 基金详情

RNA Targeted Drug Discovery and Development for Parkinson Disease

RNA Targeted Drug Discovery and Development for Parkinson Disease
帕金森病的 RNA 靶向药物发现和开发
批准号:
10392570
负责人:
Matthew D Disney
金额:
$85.11万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-01 至 2023-05-31

项目摘要

项目成果

Matthew D Disney的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 帕金森氏病(PD)是一种常见的、进展性和致残性的疾病,无法治愈。积累 来自人类遗传学、细胞生物学和动物模型研究的证据表明,α-突触核蛋白是一种关键蛋白质, 因为它错误折叠并形成可以在神经元中传播的纤维,这一现象可以解释 疾病的进行性和出现包括痴呆症在内的其他令人不安的症状 随着时间的推移。病理性α-突触核蛋白聚集的一个强大驱动因素是它在大脑中的浓度,如 SNCA基因座倍增的个体患早发性帕金森病和带有基因的痴呆 剂量效应。因此,降低α-突触核蛋白的表达是治疗帕金森病的一种看似合理的疾病改善策略。 这种方法针对疾病的根本致病机制,并有可能减轻 下游的病理事件级联,减缓神经退化。 使用一系列创新的化学和细胞生物学方法,我们已经识别出具有 不同的化学类型选择性地与SNCA 5‘非翻译区的调控元件结合,抑制 翻译,并降低稳定状态的α-突触核蛋白水平,从而导致细胞保护。转录组-和 全蛋白质组的研究表明,铅小分子,称为Synucleozid,比 SCNA定向的siRNA。使用Synucleozid作为原型,我们已经确定了其他不同的支架 降低α-突触核蛋白水平,并具有定义的血脑屏障通透性良好的特性 根据Lipinksi规则5,CNS药物的性质和CNS-MPO计算。 在这个蓝图神经疗法项目中,我们将使用高度定制的 系统的药物发现和开发漏斗。在目标1(UG3)中,我们将采用目标验证、选择性 并采用体外DMPK驱动的方法寻找最佳支架,以推进药物的早期应用 化学研究定义结构-活性和结构-性质关系。使用迭代轮次 优化,化合物将使用全面的体外和基于细胞的筛选漏斗进行评估 为进入UH3阶段做准备。我们还将完成转录组和蛋白质组范围的选择性 帕金森病患者来源的细胞的研究,后续的AIMS(UH3)将包括体内机制的证明,治疗 指数评估和启用IND的研究,所有这些都在第一阶段临床试验中达到顶峰。
英文摘要
Project Summary Parkinson's disease (PD) is a common, progressive and disabling condition with no cure. Accumulating evidence from human genetics, cell biology and animal model studies suggest that α-synuclein is a key protein, as it misfolds and forms fibrils that can propagate across neurons, a phenomenon that can account for the progressive nature of the disease and the emergence of additional disturbing symptoms including dementia over time. A strong driver of pathological α-synuclein aggregation is its concentration in the brain, as individuals with multiplication of the SNCA gene locus develop early onset PD and dementia with a gene dosage effect. Thus, reducing α-synuclein protein expression is a plausible disease modifying strategy for PD. This approach targets the root pathogenetic mechanism of the disease and has the potential to mitigate downstream cascades of pathologic events and slow down neurodegeneration. Using a series of innovative chemical and cell biologic approaches, we have identified small molecules with diverse chemotypes that selectively bind to a regulatory element in the SNCA 5' untranslated region, repress translation, and reduce steady state α-synuclein protein levels leading to cytoprotection. Transcriptome- and proteome-wide studies show that the lead small molecule, named Synucleozid, is more selective than an SCNA-directed siRNA. Using Synucleozid as a prototype, we have identified additional diverse scaffolds that reduce α-synuclein protein levels and have favorable properties for blood-brain barrier penetrance, as defined by Lipinksi's Rule of 5, properties of CNS drugs, and CNS-MPO calculations. In this Blueprint Neurotherapeutics project, we will optimize these compounds using a highly tailored systematic drug discovery and development funnel. In Aim 1 (UG3), we will take a target validation, selectivity, and in vitro DMPK-driven approach to identify the optimal scaffolds to advance to early stage medicinal chemistry studies to define structure-activity and structure-property relationships. Using iterative rounds of optimization, compounds will be evaluated using a comprehensive in vitro and cell-based screening funnel in preparation for entering the UH3 phase. We will also complete transcriptome- and proteome-wide selectivity studies in PD patient-derived cells, Subsequent aims (UH3) will include in vivo proof of mechanism, therapeutic index assessment, and IND-enabling studies, all culminating in a Phase 1 clinical trial.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Design of precision small molecules targeting RNA repeating transcripts to manipulate and study disease biology
  • 批准号:
    10380131
  • 项目类别:
  • 资助金额:
    $138.75万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Disney
  • 依托单位:
Targeted degradation of RNAs by using small molecules
  • 批准号:
    10374774
  • 项目类别:
  • 资助金额:
    $66.16万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Disney
  • 依托单位:
Design of precision small molecules targeting RNA repeating transcripts to manipulate and study disease biology
  • 批准号:
    10595458
  • 项目类别:
  • 资助金额:
    $72.54万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Disney
  • 依托单位:
Targeted degradation of RNAs by using small molecules
  • 批准号:
    10661487
  • 项目类别:
  • 资助金额:
    $66.16万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Disney
  • 依托单位:
国内基金
海外基金
柳枝稷miR156-targeted PvSPLs调控木质素合成的分子机制研究
miR156-targeted PvSPL转录因子调控柳枝稷分蘖发育的分子机制